Adrenocortical carcinomas: Surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group

被引:395
作者
Icard, P
Goudet, P
Charpenay, C
Andreassian, B
Carnaille, B
Chapuis, Y
Cougard, P
Henry, JF
Proye, C
机构
[1] Hop Gen, Serv Chirurg Viscerale & Urgences, F-21033 Dijon, France
[2] Hop Bichat Beaujon, Serv Chirurg Thorac, F-75018 Paris, France
[3] Hop Cote Nacre, Serv Chirurg Thorac, F-14033 Caen, France
[4] Hop Cochin, Serv Chirurg Viscerale & Endocrienne, F-75674 Paris 14, France
[5] Hop Enfants La Timone, Serv Chirurg Endocrinienne, F-13005 Marseille, France
[6] Hop Claude Hurriez, Clin Chirurg Est, F-59037 Lille, France
关键词
D O I
10.1007/s00268-001-0047-y
中图分类号
R61 [外科手术学];
学科分类号
摘要
Because of the rarity of adrenocortical carcinoma, survival rates and the prognosis for patients who have undergone operation are not well known. The purpose of the French Association of Endocrine Surgery was to evaluate these factors over an 18-year period. A trend study was associated to assess changes in the clinical and biochemical presentations as well as the surgical evolution. A total of 253 patients (158 women, 95 men) with a mean age of 47 years were included. Cushing syndrome was the main clinical presentation (30%), and hormonal studies revealed secreting tumors in 66% of the cases. Altogether, 72% (n = 182) of patients underwent resection for cure, and 41.5% (n = 105) of them had an extensive resection because of metastatic cancer. A lymphadenectomy was performed in 32.5% (n = 89) of the cases. The operative mortality was 5.5% (n = 14). Patients were given mitotane as adjuvant therapy in 53.8% of the cases (n = 135), The results of staging were stage I in 16 patients (6.3%), stage II (local disease) in 126 patients (49.8%), stage III (locoregional disease) in 57 patients (22.5%), and stage IV (metastases) in 54 patients (21.3%), Neither tumor staging nor the rate of curative surgery changed during the study period. More subcostal incisions were performed, and the use of mitotane increased significantly. The 5-year actuarial survival rates were 38% overall, 50% in the curative group, 66% for stage I, 58% for stage II, 24% for stage III, and 0% for stage TV. Multivariate analysis showed that mitotane benefited only the group of patients not operated on for cure. A better prognosis was found in patients operated on after 1988 (p = 0.04), in those with precursor-secreting tumors (p = 0.005), and in those at local stages of the disease (p = 0.0003), Thus mitotane benefited only patients not operated on for cure. Curative resection, precursor secretion, recent diagnosis, and local stage were favorably associated with survival.
引用
收藏
页码:891 / 897
页数:7
相关论文
共 31 条
[1]  
Chapuis Y, 1998, Chirurgie, V123, P61, DOI 10.1016/S0001-4001(98)80040-8
[2]  
COHN K, 1986, SURGERY, V100, P1170
[3]   THE RISK OF DETERMINING RISK WITH MULTIVARIABLE MODELS [J].
CONCATO, J ;
FEINSTEIN, AR ;
HOLFORD, TR .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) :201-210
[4]  
DIDOLKAR MS, 1981, CANCER-AM CANCER SOC, V47, P2153, DOI 10.1002/1097-0142(19810501)47:9<2153::AID-CNCR2820470908>3.0.CO
[5]  
2-6
[6]   Population-based study of the treatment and prognosis of carcinoma of the rectum [J].
Goudet, P ;
Roy, P ;
Arveux, I ;
Cougard, P ;
Faivre, J .
BRITISH JOURNAL OF SURGERY, 1997, 84 (11) :1546-1550
[7]  
GRONDAL S, 1990, EUR J SURG ONCOL, V16, P500
[8]   OPTIMAL TREATMENT OF ADRENOCORTICAL CARCINOMA WITH MITOTANE - RESULTS IN A CONSECUTIVE SERIES OF 96 PATIENTS [J].
HAAK, HR ;
HERMANS, J ;
VANDEVELDE, CJH ;
LENTJES, EGWM ;
GOSLINGS, BM ;
FLEUREN, GJ ;
KRANS, HMJ .
BRITISH JOURNAL OF CANCER, 1994, 69 (05) :947-951
[9]  
HARRELL FE, 1985, CANCER TREAT REP, V69, P1071
[10]   Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection [J].
Harrison, LE ;
Gaudin, PB ;
Brennan, MF .
ARCHIVES OF SURGERY, 1999, 134 (02) :181-185